Table 1.
Baseline characteristics of studies including >250 patients (n = 23)
| Study | Year | Study design (no. centers) | Sample size | Age, y | STS score, % | Inclusion period | Left ventricle ejection fraction, % | Peripheral vascular disease, % | Diabetes mellitus, % | Valve type | Follow-up, mo∗ | Approach for TAVI | Mortality at 30 d |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bjerre Thygesen et al9 | 2014 | Prospective (1) | 258 | na | na | na | na | na | na | 100% SE | na | na | na |
| Urena et al10 | 2014 | Retrospective (8) | 1556 | 80.5 | 7.5 | January 2005 to February 2013 | 55.5 | na | 31.1 | 55.1% BE 44.9% SE |
22 | na | 7% |
| Nazif et al11 | 2015 | Retrospective (21) | 1973 | 84.5 | 11.4 | May 2007 to September 2011 | 53.7 | 42.4 | 36 | 100% BE | 12 | na | 6.6% |
| Van Gils et al12 | 2017 | Retrospective (4) | 306 | 83 | 6.3 | May 2008 to February 2016 | na | 22 | 30 | 38.2% SE 34.7% SE 27.1% ME |
12 | na | 7% |
| Raelson et al13 | 2017 | Retrospective (1) | 578 | 85.5 | na | March 2009 to December 2014 | na | na | na | 21% SE 79% BE |
1 | na | na |
| Dumonteil et al14 | 2017 | Retrospective (14) | 250 | 84 | 6.3 | October 2012 to May 2014 | 58.3 | na | 22.5 | 100% ME | 12 | 100% Transfemoral | 4% |
| Kaplan et al15 | 2019 | Retrospective (1) | 594 | 81.6 | na | January 2011 to December 2017 | na | na | na | na | 12 | na | na |
| Chamandi et al16 | 2018 | Prospective (9) | 1692 | 81.5 | 10.9 | May 2009 to February 2015 | na | na | 33.1 | 50.3% BE 49.7% SE |
48 | na | 42.3% |
| Gaede et al17 | 2018 | Retrospective (1) | 1025 | 81.9 | na | 2010-2015 | na | 21.1 | 33.3 | na | 2.4 | na | na |
| Gonska et al18 | 2018 | Prospective (1) | 612 | 80.4 | 6.5 | February 2014 to September 2016 | 57.5 | na | 29.9 | 58.8% BE 36.7% ME 4.4% SE |
12 | na | 1.3% |
| Marzahn et al19 | 2018 | Retrospective (1) | 856 | 80.5 | na | July 2008 to May 2015 | 57.5 | na | 38 | 37.4% SE 57.8% BE 4.8% ME |
12 | 100% Transfemoral | na |
| Nadeem et al20 | 2018 | Retrospective (1) | 672 | 81.4 | 7.4 | 2011-2017 | 53.8 | 21.5 | 41 | na | 12 | na | na |
| Campelo-Parada et al21 | 2018 | Retrospective (2) | 347 | na | na | May 2010 to December 2015 | 54.6 | na | 37.3 | 100% BE | 1 | 77.8% Transfemoral | na |
| Mirolo et al22 | 2018 | Retrospective (1) | 936 | na | na | October 2009 to January 2017 | na | na | na | 95% BE 5% SE |
2.3 | na | na |
| Van Gils et al23 | 2018 | Retrospective (1) | 291 | 79 | na | January 2012 to December 2015 | na | na | 34 | 42% SE 51.5% BE 6.5% ME |
12 | 94% transfemoral 6% transsubclavian |
5% |
| Takahashi et al24 | 2018 | Retrospective (4) | 1621 | 84.3 | na | January 2010 to December 2014 | na | na | na | 72.5% SE | 13 | na | na |
| Chan et al25 | 2018 | Retrospective (2) | 913 | 81.6 | na | January 2012 to December 2017 | na | na | na | na | 12 | na | na |
| Ghannam et al26 | 2019 | Retrospective (1) | 573 | 79.8 | 6.4 | January 2012 to September 2017 | 57.2 | 45.8 | 37.8 | 100% SE | 17.1 | na | na |
| Costa et al27 | 2019 | Prospective (1) | 1116 | 82 | 4.4 | June 2007 to February 2018 | 53.3 | na | 28.9 | 61.8% SE 27.2% BE 0.5% ME 10.5% Others |
72 | 97% transfemoral 3% others |
3.9% |
| Dolci et al28 | 2019 | Retrospective (1) | 266 | 80 | na | February 2014 to February 2018 | 53 | 22 | 28 | 100% BE | 12 | 84% transfemoral 16% transapical |
na |
| Tovia-Brodie et al29 | 2019 | Prospective (1) | 795 | 82.5 | na | April 2012 to December 2016 | na | na | na | na | 28.2 | na | na |
| Junquera et al30 | 2019 | Retrospective (2) | 676 | 82 | 5 | May 2007 to March 2017 | 57.4 | na | 31.2 | 60.5% BE 35.2% SE 0.7% ME 0.3% others |
12 | 64.8% transfemoral | na |
| Meduri et al31 | 2019 | Prospective (1) | 704 | 82.5 | 6.6 | na | na | 28.2 | 30.9 | 34% SE 66% ME |
12 | na | na |
| Total | na | 79 | 18,610 | 81.8 (43-102) | 7.1 (0.74-34) | January 2005 to February 2018 | 55.6 | 29 | 32.6 | SE 38% BE 46% ME 13.5% others 2.5% |
16 | 88.2% transfemoral 2.3% transapical 0.9% transsubclavian Others 8.7% |
9.6% |
Values are n (%). STS score, Society of Thoracic Surgeons Risk Score; TAVI, transaortic valve implantation; na, not available; SE, self-expandable; BE, balloon-expandable; ME, mechanically expandable.
∗
Follow-up is reported as mean or median as given by the authors.